**Supplementary Table 1*.*** *Reduced odds for a severe infection in the follow up (post-index) period, with IgPro10, adjusting for covariates: A general linear model in matched cohorts\* restricted to patients with at least 6 months of follow up.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | **95% confident limits** | |  |
| **Pre-index (baseline) independent variable** | **OR** | **Lower limit** | **Upper limit** | **p-value** |
| IgPro10 | 0.64 | 0.25 | 1.68 | 0.3664 |
| Neutropenia | 0.49 | 0.20 | 1.20 | 0.1181 |
| ≥1 chemotherapy lines | 1.64 | 0.75 | 3.60 | 0.2144 |
| Age ≥65 | 1.08 | 0.43 | 2.69 | 0.8725 |
| ≥4 prior infections | 1.12 | 0.34 | 3.74 | 0.8543 |
| Normal serum IgG | 0.50 | 0.16 | 1.53 | 0.2225 |
| Hypogammaglobulinemia | 0.66 | 0.23 | 1.90 | 0.4423 |
| CLL | 1.03 | 0.23 | 4.52 | 0.9741 |
| MM | 1.15 | 0.30 | 4.32 | 0.8404 |
| NHL | 0.69 | 0.22 | 2.15 | 0.5253 |

\*Matching was performed with a 1:2 ratio of IgPro10 cohort to non-IgRT cohort (77 IgPro10 patients; 154 non-IgRT patients).

CLL, chronic lymphocytic leukemia; IgG, immunoglobulin G; IgRT, immunoglobulin replacement therapy; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; OR, odds ratio.